<p>BioCryst 制药公司（BCRX）刚刚获得了一个重要的催化剂，FDA 批准了 Orladeyo 的口服颗粒剂型，适用于 2 岁至 12 岁以下的遗传性血管性水肿儿童，这为一个新的可开发市场打开了大门。</p>
<p>请查看我们对 BioCryst 制药公司的最新分析。</p>
<p>尽管有这个催化剂，BioCryst 过去一年总股东回报约为负 2%，而过去三个月的股价回报大约为负 10%，这表明尽管管理层在追求 Astria 收购和董事会继任计划，但势头正在减弱。</p>
<p>如果这个 HAE 更新让你更广泛地思考医疗保健，那么现在可能是探索医疗保健股票中其他潜在机会的好时机。</p>
<p>然而，尽管收入增长达到两位数，且朝着盈利的方向发展，股票仍以远低于分析师目标的价格交易，投资者现在面临一个关键问题：这是一个定价错误的增长故事，还是市场已经在折扣未来的表现？</p>
<h2>最受欢迎的叙述：65% 被低估</h2>
<p>随着 BioCryst 收盘价为 7.13 美元，而叙述的公允价值为 20.40 美元，预期之间的脱节形成了显著的长期估值差距。</p>
<blockquote>
<p><em>来自欧洲业务出售和加速偿债的显著财务灵活性，使 BioCryst 能够部署资本以推进产品管线、进行有针对性的并购或许可，可能创造额外的未来收入流并支持更强的净利润率。</em></p>
</blockquote>
<p>阅读完整的叙述。</p>
<p>好奇这个资本储备如何转变为如此高的估值？这个叙述依赖于加速的收入、急剧提高的利润率和更高的未来收益倍数。想看看支撑 20 美元以上公允价值的确切假设吗？</p>
<p><strong>结果：公允价值为 20.40 美元（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，这取决于 Orladeyo 保持主导地位，因为日益激烈的 HAE 竞争和早期管线的挫折可能迅速削弱这些乐观的假设。</p>
<p>了解 BioCryst 制药叙述的关键风险。</p>
<h2>自建 BioCryst 制药叙述</h2>
<p>如果你对这个故事有不同的看法，或者想自己深入数字分析，你可以在几分钟内构建一个量身定制的视角：按你的方式进行。</p>
<p>进行 BioCryst 制药研究的一个很好的起点是我们的分析，强调 4 个关键收益和 2 个可能影响你投资决策的重要警示信号。</p>
<h2>寻找更多投资想法？</h2>
<p>在你继续之前，通过扫描 Simply Wall Street 上精心挑选的股票想法来考虑你的下一步行动，这些想法你可能不想错过。</p>
<ul>
<li>通过审查这些 913 只被低估的股票，探索潜在的价值机会，这些股票基于现金流，市场可能今天在错误定价。</li>
<li>通过查看这 26 只正在塑造企业和消费者使用智能技术的 AI 便士股票，关注创新趋势。</li>
<li>审查这 13 只收益率超过 3% 的股息股票，即使在市场波动时也可能帮助支持收入流。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不意图作为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的全自动塔。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

BioCryst制药

<p>BioCryst 制药（BCRX）获得 FDA 批准，推出适用于 2 岁至 12 岁以下儿童的 Orladeyo 口服颗粒剂，治疗遗传性血管水肿。尽管如此，该公司的股票表现不佳，过去一年总股东回报率为-2%，过去三个月股价回报率为-10%。该股票被认为被低估，公允价值为 20.40 美元，而当前价格为 7.13 美元。公司在未来增长方面具有显著的财务灵活性，但面临来自竞争加剧和产品管线挫折的风险</p>

<p>BioCryst Pharmaceuticals (BCRX) just picked up a meaningful catalyst, with the FDA clearing an oral pellet version of Orladeyo for children aged 2 to under 12 with hereditary angioedema, opening a newly addressable niche.</p>
<div class="lb-trans"><p>BioCryst 制药公司（BCRX）刚刚获得了一个重要的催化剂，FDA 批准了 Orladeyo 的口服颗粒剂型，适用于 2 岁至 12 岁以下的遗传性血管性水肿儿童，这为一个新的可开发市场打开了大门。</p>
</div><p>See our latest analysis for BioCryst Pharmaceuticals.</p>
<div class="lb-trans"><p>请查看我们对 BioCryst 制药公司的最新分析。</p>
</div><p>Despite this catalyst, BioCryst’s 1 year total shareholder return of around minus 2 percent and a 3 month share price return of roughly minus 10 percent suggest momentum has been fading, even as management pursues the Astria acquisition and board succession plans.</p>
<div class="lb-trans"><p>尽管有这个催化剂，BioCryst 过去一年总股东回报约为负 2%，而过去三个月的股价回报大约为负 10%，这表明尽管管理层在追求 Astria 收购和董事会继任计划，但势头正在减弱。</p>
</div><p>If this HAE update has you thinking more broadly about healthcare, it could be a good moment to explore other potential opportunities across healthcare stocks.</p>
<div class="lb-trans"><p>如果这个 HAE 更新让你更广泛地思考医疗保健，那么现在可能是探索医疗保健股票中其他潜在机会的好时机。</p>
</div><p>Yet with the stock still trading at a steep discount to analyst targets despite double digit revenue growth and a path toward profitability, investors now face a key question: is this a mispriced growth story, or is the market already discounting what comes next?</p>
<div class="lb-trans"><p>然而，尽管收入增长达到两位数，且朝着盈利的方向发展，股票仍以远低于分析师目标的价格交易，投资者现在面临一个关键问题：这是一个定价错误的增长故事，还是市场已经在折扣未来的表现？</p>
</div><h2>Most Popular Narrative Narrative: 65% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：65% 被低估</h2>
</div><p>With BioCryst closing at $7.13 versus a narrative fair value of $20.40, the disconnect in expectations sets up a striking long term valuation gap.</p>
<div class="lb-trans"><p>随着 BioCryst 收盘价为 7.13 美元，而叙述的公允价值为 20.40 美元，预期之间的脱节形成了显著的长期估值差距。</p>
</div><blockquote>
<p><em>Significant financial flexibility from the sale of the European business and accelerated debt paydown sets BioCryst up to deploy capital for pipeline advancement, targeted M and A, or in licensing, potentially creating additional future revenue streams and supporting stronger net margins.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>来自欧洲业务出售和加速偿债的显著财务灵活性，使 BioCryst 能够部署资本以推进产品管线、进行有针对性的并购或许可，可能创造额外的未来收入流并支持更强的净利润率。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整的叙述。</p>
</div><p>Curious how this capital war chest turns into that lofty valuation? The narrative leans on accelerating revenue, sharply higher margins, and a richer future earnings multiple. Want to see the exact assumptions that power that $20 plus fair value?</p>
<div class="lb-trans"><p>好奇这个资本储备如何转变为如此高的估值？这个叙述依赖于加速的收入、急剧提高的利润率和更高的未来收益倍数。想看看支撑 20 美元以上公允价值的确切假设吗？</p>
</div><p><strong>Result: Fair Value of $20.40 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 20.40 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, this hinges on Orladeyo remaining dominant, as rising HAE competition and early stage pipeline setbacks could quickly undermine those bullish assumptions.</p>
<div class="lb-trans"><p>然而，这取决于 Orladeyo 保持主导地位，因为日益激烈的 HAE 竞争和早期管线的挫折可能迅速削弱这些乐观的假设。</p>
</div><p>Find out about the key risks to this BioCryst Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>了解 BioCryst 制药叙述的关键风险。</p>
</div><h2>Build Your Own BioCryst Pharmaceuticals Narrative</h2>
<div class="lb-trans"><h2>自建 BioCryst 制药叙述</h2>
</div><p>If you see the story differently or want to dig into the numbers yourself, you can build a tailored view in just minutes: Do it your way.</p>
<div class="lb-trans"><p>如果你对这个故事有不同的看法，或者想自己深入数字分析，你可以在几分钟内构建一个量身定制的视角：按你的方式进行。</p>
</div><p>A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.</p>
<div class="lb-trans"><p>进行 BioCryst 制药研究的一个很好的起点是我们的分析，强调 4 个关键收益和 2 个可能影响你投资决策的重要警示信号。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>Before you move on, consider your next move by scanning hand picked stock ideas on Simply Wall Street that you may not want to overlook.</p>
<div class="lb-trans"><p>在你继续之前，通过扫描 Simply Wall Street 上精心挑选的股票想法来考虑你的下一步行动，这些想法你可能不想错过。</p>
</div><ul>
<li>Explore potential value opportunities by reviewing these 913 undervalued stocks based on cash flows that the market may be mispricing today.</li>
<li>Focus on innovation trends by looking at these 26 AI penny stocks that are shaping how businesses and consumers use intelligent technology.</li>
<li>Review these 13 dividend stocks with yields &gt; 3% that may help support an income stream even when markets are choppy.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过审查这些 913 只被低估的股票，探索潜在的价值机会，这些股票基于现金流，市场可能今天在错误定价。</li>
<li>通过查看这 26 只正在塑造企业和消费者使用智能技术的 AI 便士股票，关注创新趋势。</li>
<li>审查这 13 只收益率超过 3% 的股息股票，即使在市场波动时也可能帮助支持收入流。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章不意图作为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的全自动塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

在 FDA 扩大 ORLADEYO 对年轻遗传性血管性水肿患者的使用范围后，BioCryst (BCRX) 的估值